HONG KONG, Oct 9, 2015 - (ACN Newswire) - The leading innovative pharmaceutical company with strong R&D capability and global vision in China market-Luye Pharma Group Ltd. (the "Company", together with its subsidiaries, "Luye", stock code: 2186.HK), announced that the United States Food and Drug Administration (the "FDA") has confirmed that no additional clinical trials are needed for the New Drug Application ("NDA") submission for Risperidone Extended-release Microspheres for Injection ("LY03004") in the U.S. This will significantly cut down costs and time required for obtaining FDA approval for LY03004. This is the first truly innovative drug manufactured in China that passes the audits of FDA and it is about to enter the NDA progress. This breakthrough marks Luye Pharma and China's first self-developed microsphere preparation products will enter the US market in the near future.
Humphries Pharmaceutical Consulting, LLC (HPC) BD Leader Zhao said that this is an essential way for Chinese pharmaceutical companies to accomplish internationalization and it again represents the breakthrough of domestic pharmaceutical enterprises. It is more difficult than simply developing generic drugs. The breakthrough not only implies that China's R & D level, the international registration standards and international patent awareness have all reached a standard level, but also means that domestic pharmaceutical enterprises have become more and more familiar with the international drug trial game.
LY03004 is formulated as extended release microspheres for intramuscular injection for the treatment of schizophrenia and/or schizoaffective disorders. After LY03004 comes to the market, it is expected to improve medication compliance in patients with schizophrenia which is a common issue with oral antipsychotic drugs and would simplify treatment regimen since it needs to be injected only once every two weeks. Furthermore, LY03004 has significant advantages over another marketed drug, for example, there is no need to administer oral formulation during the three weeks after the first injection of LY03004 compared to the marketed drug. The stable plasma drug level can be reached much faster with LY03004 as compared to that marketed drug. According to World Health Organization, schizophrenia affects more than 21 million people worldwide, and one in two people living with schizophrenia does not receive treatment for the condition. LY03004 developed by Luye Pharma will bring gospel to a large number of patients living with schizophrenia.
On 10 September 2015, the Company had a meeting with the FDA on LY03004. The FDA confirmed that the results of the completed pivotal study involving a total of 108 patients enrolled in the U.S. can be used to support a NDA submission via the 505(b)(2) pathway for LY03004 without additional clinical trials. The Company is currently preparing the NDA report for LY03004.
Mr. LIU Dianbo, Executive Chairman and Chief Executive Officer of Luye Pharma Group Ltd. said, "The FDA's confirmation of no additional clinical trials are needed for the NDA submission for LY03004 in the U.S is a powerful proof of Luye's strong pharmaceutical research and development capabilities and marks Luye Pharma's another major progress in International Registration and a delightful step in accomplishing internationalization. LY03004 has good market potential and will enrich the Company's product pipeline. In addition to obtaining regulatory approval in the U.S., the Company is also targeting to obtain regulatory approval for LY03004 in Europe and Japan. Apart from LY03004, the Company is currently developing several new pharmaceutical products in the U.S., Europe and Japan. We will unswervingly implement the established strategic objectives, continued to invest in R & D to expand innovative product lines, consolidate existing advantages and strive to become the most respected leading pharmaceutical company in the globe."
About Luye Pharma Group Ltd
Luye is a leading innovative pharmaceutical company in China and focuses on developing, producing, marketing and selling innovative pharmaceutical products in three of the largest and fastest growing therapeutic areas in the PRC-oncology, cardiovascular system and alimentary tract and metabolism. The five core products of the Group enjoys leading position in their therapeutic field respectively and accounted for 74.8% of total revenue in the year 2014. The revenue of patent products mounted to 86.5% in 2014. Sales network covers 30 province and cities in China, over 8,500 hospitals. Five leading production bases are in Yantai, Nanjing, Beijing and Luzhou and product lines are all recognized by new GMP in China. The Group have rich product pipeline with 21 products under research. The Group is proactively expanding overseas market and 7 products are under the process of registration overseas, among which 3 products have entered into the FDA clinical phase and 1 has gained the approval from FDA that no additional clinical trials are needed for the NDA submission for LY03004 in the U.S.
Issued by Porda Havas International Finance Communications Group for and on behalf of Luye Pharma Group Ltd.
Source: Luye Pharma Group Ltd
Contact:
Porda Havas International Finance Communications Group Mr. Paul Sham Tel: +852 3150 6730 paul.sham@pordahavas.com Ms. Susan Chen Tel: +852 3150 6733 susan.chen@pordahavas.com Ms. Rachel Liu Tel: +852 3150 6767 rachel.liu@pordahavas.com Fax: +852 3150 6728
Copyright 2015 ACN Newswire . All rights reserved.
